For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ORGANIZATION
ORGANIZATION
- New Year’s Message: On behalf of the JPMA, I would like to express our best wishes for a Happy New Year as we see the start of 2012.
January 5, 2012
- JGA to Push for Changing Brand-Based Product Names to Generic Names
December 28, 2011
- JGA President Sawai Says Additional Price Cuts for Generics “In No Way Acceptable”
December 27, 2011
- FPMAJ, JPMA “Truly Regret” Additional Price Cuts for Long-Listed, Generic Drugs
December 27, 2011
- JPMA's Kawabe Says Additional Price Cut for Long-Listed Products is “Not a Rule”
December 22, 2011
- Cancer Patient Groups Submit Petition Asking for Elimination of Drug Lag
December 20, 2011
- Doctor Survey Shows AD at Top of Most Medically Significant Diseases in 2020
December 20, 2011
- GSK President Fauchet Appointed New Chairman, EFPIA Japan
December 20, 2011
- Mr Sawai of JGA Announces “Absolute Opposition” to Add’l Price Reduction for Generics
December 20, 2011
- JCQHC Calls Attention to Contraindication of Coadministration
December 19, 2011
- Drug Pricing Subcommittee President Bessho Calls for Correction in “Across-the-Board” Bundling
December 15, 2011
- Drug Expenditure Ratio Should Be Fixed: Professor Endo, Gakushuin University
December 15, 2011
- Industry Reps Call for 4-6 Year Extension of Trial for Premium for New Drug Development
December 15, 2011
- Share of Generics Virtually Unchanged at 23.2%: JGA Flash Report
December 14, 2011
- 129 Hospitals Stopped Providing Services in Ophthalmology Since 2008: JOA
December 13, 2011
- JMA Announces View on TPP Agreement on Website
December 12, 2011
- Osaka Bio Fund Chooses Tokyo Drug Discovery Venture as No. 3 Investment Project
December 9, 2011
- JACDS Engaged in Petition Drive to Prevent Ban on “Dispensing Point” Services
December 9, 2011
- Shortest Development, Review Periods for New Drugs in 2010: OPIR Report
December 8, 2011
- FBRI to Open Nation’s Biggest Manufacturing Facility for Investigational PET Drugs
December 7, 2011
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…